MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Compass Pathways plc (NASDAQ: CMPS)*
Organization & Developments: Compass Pathways
Parents
Compass Pathways plc (NASDAQ: CMPS)*
Children
*COMPASS is currently running the world’s first large-scale psilocybin therapy clinical trial, in 20 sites across Europe and North America.
*COMPASS Pathways (NASDAQ: CMPS) is a mental healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, working to find better ways to help and empower people who are suffering with mental health challenges.
*The company’s first major initiative is developing psilocybin therapy for treatment-resistant depression (TRD), for which program they received FDA Breakthrough Therapy designation in 2018.
2022: Compass Pathways: De-Risked (But Still Risky) Psychedelics Play Enters Phase 3_ seekingalpha.com
2024: Compass Pathways cuts 30% of workforce on Phase 3 trial delays
2024: Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity_seekingalpha.com
2024: Compass Pathways: No Near-Term Fix For Struggling Psychedelic Therapy Pioneer
2024: Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
2025: Breakthrough Depression Treatment Reaches Critical Phase 3 Milestone: COMP360 Psilocybin Trial Fully Enrolled
2025: Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
2025: Compass Pathways: Betting On The Future Of Psilocybin Therapy_seekingalpha.com
2025: Positive Outlook for COMPASS Pathways: Buy Rating Backed by Promising Developments in Mental Health Treatments and Strong Financial Position
Jumps
Finance & Acquisitions: Compass Pathways
Key People: Compass Pathways